Trypsin, Crystallized

Summary

Trypsin, Crystallized (CHEMBL2108821) is a phase-3 clinical-stage unknown (ATC M09AB52) targeting PLG; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: M09AB52 (+2 more)
• Targets: 1 (PLG)
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108821
Name	Trypsin, Crystallized
Type	Unknown
Max phase	3
ATC	M09AB52, D03BA01, B06AA07

Also known as: Crystallized trypsin, EC 3.4.21.4, Porcine trypsin, Trypsin, Trypsin crystallized, Trypsin recombinant porcine, porcine, porcine cationic, unspecified form, crystallized, TRYPSIN, CRYSTALLIZED

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PLG	plasminogen	Binding	6.8	4.6%	P00747

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): PLG.

Top Reactome pathways

6 total, by targets touching each:

Pathway	Targets	Genes
Platelet degranulation	1	PLG
Degradation of the extracellular matrix	1	PLG
Activation of Matrix Metalloproteinases	1	PLG
Signaling by PDGF	1	PLG
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	PLG
Dissolution of Fibrin Clot	1	PLG

Dominant GO biological processes

GO term	Targets
proteolysis	1
blood coagulation	1
negative regulation of cell population proliferation	1
negative regulation of cell-substrate adhesion	1
protein processing	1
extracellular matrix disassembly	1
tissue regeneration	1
fibrinolysis	1
positive regulation of blood vessel endothelial cell migration	1
myoblast differentiation	1
muscle cell cellular homeostasis	1
tissue remodeling	1
biological process involved in interaction with symbiont	1
negative regulation of fibrinolysis	1
positive regulation of fibrinolysis	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

11 molecules share ≥1 primary target. Top 11 by shared-target count:

Molecule	Source	Status	Shared targets
AMINOCAPROIC ACID	ChEMBL	Phase 4 (approved)	PLG
BEROTRALSTAT	ChEMBL	Phase 4 (approved)	PLG
MELAGATRAN	ChEMBL	Phase 4 (approved)	PLG
PENTAMIDINE	ChEMBL	Phase 4 (approved)	PLG
TELAPREVIR	ChEMBL	Phase 4 (approved)	PLG
TRANEXAMIC ACID	ChEMBL	Phase 4 (approved)	PLG
DABIGATRAN	ChEMBL	Phase 3	PLG
GABEXATE	ChEMBL	Phase 3	PLG
MILVEXIAN	ChEMBL	Phase 3	PLG
NAFAMOSTAT	ChEMBL	Phase 3	PLG
EFEGATRAN	ChEMBL	Phase 2	PLG